Cargando…

Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting

BACKGROUND: With large waves of infection driven by the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), alongside evidence of waning immunity after the booster dose of coronavirus disease 2019 (Covid-19) vaccine, several countries have begun giving at-ris...

Descripción completa

Detalles Bibliográficos
Autores principales:	Magen, Ori, Waxman, Jacob G., Makov-Assif, Maya, Vered, Roni, Dicker, Dror, Hernán, Miguel A., Lipsitch, Marc, Reis, Ben Y., Balicer, Ran D., Dagan, Noa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Massachusetts Medical Society 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020581/ https://www.ncbi.nlm.nih.gov/pubmed/35417631 http://dx.doi.org/10.1056/NEJMoa2201688

Ejemplares similares

Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
por: Barda, Noam, et al.
Publicado: (2021)

Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting
por: Mittelman, Moshe, et al.
Publicado: (2022)

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
por: Dagan, Noa, et al.
Publicado: (2021)

Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents
por: Reis, Ben Y., et al.
Publicado: (2021)

BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age
por: Cohen-Stavi, Chandra J., et al.
Publicado: (2022)

Comparing COVID-19-related hospitalization rates among individuals with infection-induced and vaccine-induced immunity in Israel
por: Waxman, Jacob G., et al.
Publicado: (2022)

Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
por: Barda, Noam, et al.
Publicado: (2021)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Witberg, Guy, et al.
Publicado: (2022)

Adverse Effects after BNT162b2 Vaccine and SARS-CoV-2 Infection, According to Age and Sex
por: Dagan, Noa, et al.
Publicado: (2021)

BNT162b2 vaccine effectiveness in chronic kidney disease patients—an observational study
por: Bielopolski, Dana, et al.
Publicado: (2022)

Short-term Adverse Events After the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine in Adults 60 Years or Older
por: Auster, Oren, et al.
Publicado: (2022)

Protection by a Fourth Dose of BNT162b2 against Omicron in Israel
por: Bar-On, Yinon M., et al.
Publicado: (2022)

Boosting capacity of a fourth dose BNT162b2 in cancer patients
por: Debie, Yana, et al.
Publicado: (2023)

Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
por: Canetti, Michal, et al.
Publicado: (2022)

Humoral and T-Cell Response before and after a Fourth BNT162b2 Vaccine Dose in Adults ≥60 Years
por: Bar-Haim, Erez, et al.
Publicado: (2022)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Mevorach, Dror, et al.
Publicado: (2022)

Fourth BNT162b2 vaccination neutralization of omicron infection after heart transplantation
por: Peled, Yael, et al.
Publicado: (2022)

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel
por: Mevorach, Dror, et al.
Publicado: (2021)

Antibody Titers After a Third and Fourth SARS-CoV-2 BNT162b2 Vaccine Dose in Older Adults
por: Eliakim-Raz, Noa, et al.
Publicado: (2022)

Author Correction: Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
por: Canetti, Michal, et al.
Publicado: (2023)

Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose
por: Canetti, Michal, et al.
Publicado: (2022)

Humoral Response and SARS-CoV-2 Infection Risk following the Third and Fourth Doses of the BNT162b2 Vaccine in Dialysis Patients
por: Einbinder, Yael, et al.
Publicado: (2022)

Antibody response to third and fourth BNT162b2 mRNA booster vaccinations in healthcare workers in Tokyo, Japan
por: Sanada, Takahiro, et al.
Publicado: (2023)

Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine
por: Shostak, Yael, et al.
Publicado: (2021)

The Humoral Response of Patients With Cancer to Breakthrough COVID-19 Infection or the Fourth BNT162b2 Vaccine Dose
por: Cohen, Idan, et al.
Publicado: (2023)

Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study
por: Yechezkel, Matan, et al.
Publicado: (2023)

Weaker Effects of the Fourth Dose of BNT162b2 SARS-CoV-2 Vaccine on the Elderly Human Population
por: Dimeglio, Chloé, et al.
Publicado: (2023)

Blunted humoral immune response to the fourth dose of BNT162b2 COVID-19 vaccine in patients undergoing hemodialysis
por: Kanai, Daisuke, et al.
Publicado: (2023)

External validation and comparison of three prediction tools for risk of osteoporotic fractures using data from population based electronic health records: retrospective cohort study
por: Dagan, Noa, et al.
Publicado: (2017)

Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients
por: Yanay, Noa Berar, et al.
Publicado: (2021)

Duration of humoral response to the third dose of BNT162b2 vaccine in patients with solid cancer: Is fourth dose urgently needed?
por: Di Noia, Vincenzo, et al.
Publicado: (2022)

Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment
por: Lasagna, A., et al.
Publicado: (2022)

Safety of BNT162b2 mRNA COVID-19 vaccine in patients with mast cell disorders
por: Rosman, Yossi, et al.
Publicado: (2021)

Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in patients with SLE and rheumatoid arthritis
por: Assawasaksakul, Theerada, et al.
Publicado: (2022)

Longitudinal cellular and humoral immune responses after triple BNT162b2 and fourth full-dose mRNA-1273 vaccination in haemodialysis patients
por: Becker, Matthias, et al.
Publicado: (2022)

Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans
por: Dickerman, Barbra A., et al.
Publicado: (2021)

BNT162b2 mRNA vaccine elicited antibody response in blood and milk of breastfeeding women
por: Rosenberg-Friedman, Michal, et al.
Publicado: (2021)

Beyond neutralization for BNT162b2 mRNA vaccination
por: Damani-Yokota, Payal, et al.
Publicado: (2021)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Clinical and Molecular Characterization of a Rare Case of BNT162b2 mRNA COVID-19 Vaccine-Associated Myositis
por: Magen, Eli, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_19tcnaaeg5l5dvrlnuf4ql13pf